Breaking News Instant updates and real-time market news.

MRK

Merck

$53.36

-1.17 (-2.15%)

06:48
04/09/18
04/09
06:48
04/09/18
06:48

Merck: Phase 3 KEYNOTE-042 trial met primary endpoint of overall survival

Merck announced that the pivotal Phase 3 KEYNOTE-042 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, met its primary endpoint of overall survival. An interim analysis conducted by the independent Data Monitoring Committee demonstrated that treatment with KEYTRUDA resulted in significantly longer OS than platinum-based chemotherapy in patients with a PD-L1 tumor proportion score of greater than or equal to 1%. As part of a pre-specified analysis plan, OS was sequentially tested and was significantly improved in patients with a TPS of greater than or equal to 50%, with a TPS of greater than or equal to 20% and then in the entire study population with a TPS of greater than or equal to 1%. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported monotherapy studies involving patients with advanced NSCLC. Based on the recommendation of the DMC, the trial will continue to evaluate progression-free survival, which is a secondary endpoint. Results from KEYNOTE-042 will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.

  • 09

    Apr

  • 14

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 08

    May

  • 23

    Oct

MRK Merck
$53.36

-1.17 (-2.15%)

04/06/18
WBLR
04/06/18
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Incyte after metastatic melanoma study failure
William Blair analyst Katherine Xu downgraded Incyte (INCY) to Market Perform from Outperform after the company and partner Merck (MRK) announced that ECHO-301 did not meet one of the primary endpoints of improving progression-free survival and that overall survival, the other co-primary endpoint, was not expected to be met either. After taking epacadostat out of her model, the analyst's fair value estimate for Incyte drops to $88 from $170. The stock in premarket trading is down 21%, or $17.08, to $65.99. It is unclear whether the biomarker data derived from ECHO-301 could guide other Phase III studies, and whether the other Phase III studies are to continue, Xu tells investors in a research note. She sees the next key catalysts for Incyte shares as the baricitinib advisory panel on April 23, and data from Jakafi Phase II pivotal REACH1 study in steroid-refractory acute graft-versus-host disease in the first half 2018.
04/06/18
CANT
04/06/18
NO CHANGE
Target $26
CANT
Overweight
Cantor says premature to assume NewLink trial will fail like Incyte's
NewLink Genetics' (NLNK) indoximod, which acts as a tryptophan mimetic rather than an IDO enzymatic inhibitor, has shown differentiated data versus Incyte's (INCY) epacadostat, Cantor Fitzgerald analyst Mara Goldstein tells investors in a research note. NewLink is trading down 37.5%, or $2.75, to $4.57 after Incyte announced that its ECHO-301 study of epacadostat plus Merck's (MRK) Keytruda versus Keytruda alone was unsuccessful in treating advanced melanoma. Goldstein thinks assuming failure of indoximod "may be premature," but she acknowledges that NewLink shares are likely to be pressured with the company's Phase III trial end likely over a year away. If indoximod is truly differentiated, however, NewLink shares will be higher than $26 given the "now likely limited competition," Goldstein contends. She reiterates an Overweight rating on the shares with a $26 price target.
04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.

TODAY'S FREE FLY STORIES

DHI

D.R. Horton

$44.28

0.77 (1.77%)

13:10
08/14/18
08/14
13:10
08/14/18
13:10
Options
Size block of calls sold in D R Horton looks closing »

Size block of calls sold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$41.80

1.72 (4.29%)

, PFGC

Performance Food Group

$38.05

1.15 (3.12%)

13:07
08/14/18
08/14
13:07
08/14/18
13:07
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

M

Macy's

$41.80

1.72 (4.29%)

PFGC

Performance Food Group

$38.05

1.15 (3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

  • 17

    Sep

AIV

Aimco

$43.25

0.5 (1.17%)

13:07
08/14/18
08/14
13:07
08/14/18
13:07
Conference/Events
Aimco management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

A

Agilent

$67.14

1.19 (1.80%)

, CREE

Cree

$49.96

-0.32 (-0.64%)

13:07
08/14/18
08/14
13:07
08/14/18
13:07
Earnings
Notable companies reporting after market close »

Notable companies…

A

Agilent

$67.14

1.19 (1.80%)

CREE

Cree

$49.96

-0.32 (-0.64%)

VIAV

Viavi

$11.09

0.13 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 05

    Sep

  • 06

    Sep

  • 12

    Sep

KO

Coca-Cola

$45.93

0.11 (0.24%)

, PEP

PepsiCo

$112.80

-0.22 (-0.19%)

13:06
08/14/18
08/14
13:06
08/14/18
13:06
Hot Stocks
Coca-Cola's BodyArmor deal seen as negative for Pepsi, Keurig Dr Pepper »

In latest attempt to…

KO

Coca-Cola

$45.93

0.11 (0.24%)

PEP

PepsiCo

$112.80

-0.22 (-0.19%)

KDP

Keurig Dr Pepper

$23.61

-0.14 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$30.23

0.025 (0.08%)

, AKS

AK Steel

$4.20

-0.06 (-1.41%)

13:05
08/14/18
08/14
13:05
08/14/18
13:05
Periodicals
Canada near to imposing broad steel tariffs, Dow Jones says »

Canadian officials are…

X

U.S. Steel

$30.23

0.025 (0.08%)

AKS

AK Steel

$4.20

-0.06 (-1.41%)

NUE

Nucor

$63.53

0.4 (0.63%)

STLD

Steel Dynamics

$43.57

-0.1 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

IGT

International Game

$20.44

-0.12 (-0.58%)

13:05
08/14/18
08/14
13:05
08/14/18
13:05
Options
International Game call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLI

Mack-Cali Realty

$19.99

0.92 (4.82%)

13:03
08/14/18
08/14
13:03
08/14/18
13:03
Periodicals
Land & Buildings likely to push for Mack-Cali sale, Bloomberg reports »

Jonathan Litt's Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$356.33

0.29 (0.08%)

, GS

Goldman Sachs

$229.95

3.12 (1.38%)

12:56
08/14/18
08/14
12:56
08/14/18
12:56
Periodicals
Goldman not hired officially by Tesla at time of tweet, Bloomberg reports »

Goldman Sachs had not…

TSLA

Tesla

$356.33

0.29 (0.08%)

GS

Goldman Sachs

$229.95

3.12 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

DOMO

Domo

$18.38

-0.1 (-0.54%)

12:53
08/14/18
08/14
12:53
08/14/18
12:53
Hot Stocks
Breaking Hot Stocks news story on Domo »

Joshua G. James reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.91

1.25 (1.39%)

12:50
08/14/18
08/14
12:50
08/14/18
12:50
Options
8.8K Walmart Sep 92.5 - Oct 95 call spreads bought for 29c »

8.8K Walmart Sep 92.5 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

AMZN

Amazon.com

$1,916.80

21.29 (1.12%)

12:49
08/14/18
08/14
12:49
08/14/18
12:49
Periodicals
U.K's ASA says Amazon Prime's one-day claim misled customers, CNBC reports »

The U.K.'s…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 13

    Sep

CCXI

ChemoCentryx

$11.12

-1.54 (-12.16%)

12:47
08/14/18
08/14
12:47
08/14/18
12:47
Recommendations
ChemoCentryx analyst commentary  »

ChemoCentryx selloff on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$28.00

0.66 (2.41%)

12:45
08/14/18
08/14
12:45
08/14/18
12:45
Options
American Eagle call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

12:40
08/14/18
08/14
12:40
08/14/18
12:40
General news
U.S. equities are extending their rebound »

U.S. equities are…

GOOG

Alphabet

$1,240.12

5.02 (0.41%)

, GOOGL

Alphabet Class A

$1,255.80

7.04 (0.56%)

12:38
08/14/18
08/14
12:38
08/14/18
12:38
Periodicals
Alphabet invests $375M in Obamacare startup Oscar, Bloomberg reports »

Alphabet is investing…

GOOG

Alphabet

$1,240.12

5.02 (0.41%)

GOOGL

Alphabet Class A

$1,255.80

7.04 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 22

    Aug

  • 18

    Sep

  • 28

    Oct

STXB

Spirit of Texas Bancshares

$21.48

(0.00%)

12:37
08/14/18
08/14
12:37
08/14/18
12:37
Hot Stocks
Breaking Hot Stocks news story on Spirit of Texas Bancshares »

FJ Capital reports 5.21%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EKSO

Ekso Bionics

$2.84

0.16 (5.97%)

12:35
08/14/18
08/14
12:35
08/14/18
12:35
Hot Stocks
Ekso Bionics awarded $5M Department of Veterans Affairs contract 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
08/14/18
08/14
12:35
08/14/18
12:35
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

ATVI

Activision Blizzard

$71.54

1.02 (1.45%)

, EA

Electronic Arts

$131.76

0.47 (0.36%)

12:32
08/14/18
08/14
12:32
08/14/18
12:32
Hot Stocks
Game On: 'Fortnite' reportedly poses malware risk on Android »

Welcome to "Game…

ATVI

Activision Blizzard

$71.54

1.02 (1.45%)

EA

Electronic Arts

$131.76

0.47 (0.36%)

GOOG

Alphabet

$1,239.50

4.4 (0.36%)

GOOGL

Alphabet Class A

$1,255.19

6.43 (0.51%)

SSNLF

Samsung

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

DIS

Disney

$112.93

0.82 (0.73%)

CCOEY

Capcom

$0.00

(0.00%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 22

    Aug

  • 04

    Sep

  • 10

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

  • 18

    Sep

  • 28

    Oct

URBN

Urban Outfitters

$47.93

0.51 (1.08%)

12:30
08/14/18
08/14
12:30
08/14/18
12:30
Options
Put spreads in Urban Outfitters ahead of earnings next week »

Put spreads in Urban…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

YUMC

Yum China

$35.81

1.59 (4.65%)

12:25
08/14/18
08/14
12:25
08/14/18
12:25
Options
Yum China call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

ACRS

Aclaris Therapeutics

$16.86

-0.27 (-1.58%)

12:25
08/14/18
08/14
12:25
08/14/18
12:25
Conference/Events
Cantor consumer products analysts to hold analyst/industry conference call »

Analysts, along with Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

CLI

Mack-Cali Realty

$19.42

0.35 (1.84%)

12:22
08/14/18
08/14
12:22
08/14/18
12:22
Periodicals
Breaking Periodicals news story on Mack-Cali Realty »

Activist investor Litt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANSS

Ansys

$172.90

1.87 (1.09%)

12:22
08/14/18
08/14
12:22
08/14/18
12:22
Recommendations
Ansys analyst commentary  »

Ansys price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.